Г

(Print or Ta

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address o CARDOZA GEOR	2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NGNM.OB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
	(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) EOGENOMICS, INC., 12701 10/26/2011 MONWEALTH DRIVE SUITE 9 10/26/2011						X Officer (give title below) Other (specify below) CFO				
FORT MYERS, FL	2	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execution Date, if any	(Instr. 8)	ion			of (D)	Owned Following Reported Transaction(s)	6. Ownership Form:	Beneficial
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock		10/26/2011		Р		3,000	А	\$ 1.21	41,676 (1)	D	
Common Stock									20,000	I	Trust by Self

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of		3. Transaction	3A. Deemed	4.						8. Price of	9. Number of		11. Nature		
	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code)	Deriv Secur Acqu (A) o Dispo of (D (Instr	of Expiration Date Nervative (Month/Day/Year) Sequired A) or Disposed		of Underlying Securities		(Instr. 5)	Securities Beneficially Owned	Derivative Security: Direct (D) or Indirect	Beneficial	
				Code	v	(A)			Expiration Date	Title	Amount or Number of Shares				
Stock options (Right to Buy)	\$ 1.55							11/30/2010 ⁽²⁾	11/30/2014	Common Stock	150,000		0	D	
Stock options (Right to Buy)	\$ 1.46							04/14/2012 ⁽³⁾	04/14/2016	Common Stock	100,000		0	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
CARDOZA GEORGE C/O NEOGENOMICS, INC. 12701 COMMONWEALTH DRIVE SUITE 9 FORT MYERS, FL US 33913			CFO					

Signatures

/s/ George Cardoza	10/27/2011
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (2) On November 30, 2009 Mr. Cardoza was granted an option to purchase 150,000 shares. The options were all time based and vest ratable over each of Mr. Cardoza's first four anniversaries with the Company.
- (3) On April 14, 2011 Mr. Cardoza was granted an option to purchase 100,000 shares. 75% of these options vest ratably at the first three anniversary dates of the grant and 25% of the options are performance based.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

⁽¹⁾ The amount includes exempt purchases made under the Company's stock purchase plan.